Patents Assigned to University of Florida Research Foundation Incorporated
  • AAV PRODUCTION USING SUSPENSION ADAPTED CELLS
    Publication number: 20220204945
    Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 30, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Nathalie Clement, Barry John Byrne, Laura Adamson
  • Aliphatic polysulfones with improved mechanical integrity
    Patent number: 11370887
    Abstract: A polysulfone has sulfone units that are separated by alkylene units in a polymer chain or a copolymer chain where the alkylene units have at least four carbons between sulfone units. The alkylene units can include an ethenylene unit separated from the sulfone units by at least one methylene units. The polysulfones can be crosslinked for enhanced thermal stability. Membranes can be formed from the polysulfones.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: June 28, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Kenneth B. Wagener, Taylor W. Gaines, Michael Bell, Julia Grace Pribyl
  • Chemical uncouplers of respiration and methods of use thereof
    Patent number: 11365177
    Abstract: Uncoupling of respiration is a well-recognized process that increases respiration and heat production in cells. Provided herein are chemical uncouplers of respiration that are compounds of Formula (I). Also provided are methods for preventing or treating metabolic disorders and modulating metabolic processes using compound of Formula (I).
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 21, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., University of Florida Research Foundation, Incorporated
    Inventors: Bruce M. Spiegelman, Jonathan Z. Long, Hua Lin, Theodore Kamenecka, Patrick Griffin
  • REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY
    Publication number: 20220183613
    Abstract: The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 16, 2022
    Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, UNIVERSITY OF WASHINGTON, UNIVERSITY OF WASHINGTON
    Inventors: Jay NEITZ, Maureen NEITZ, James A. KUCHENBECKER, William W. HAUSWIRTH
  • PRMT5 INHIBITOR COMPOUNDS
    Publication number: 20220185792
    Abstract: A series of PRMT5 inhibitor compounds are described. The compounds are useful as PRMT5 inhibitor compounds and in the treatment of PRMT5 mediated diseases, disorders, and symptoms thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Chenglong Li, Xiaozhi Yang, Wei Zhou
  • MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE
    Publication number: 20220186258
    Abstract: Provided herein are compositions of recombinant adeno-associated virus (rAAV) particles capable of dampening the humoral immune response against rAAV in the host into which the rAAV particles are introduced. The modified genomes of these rAAV particles comprise heterologous insert nucleic acid and/or inverted terminal repeat (ITR) sequences containing one or more sequences associated with the human leukocyte antigen gene complex DR (HLA-DR) promoter. Also provided herein are methods for transducing host cells with modified rAAV particles to induce a dampened humoral immune responses in order to improve transduction efficiencies. Also provided herein are complexes comprising a modified rAAV particle and a Regulatory Factor X (RFX) transcription factor.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 16, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Arun Srivastava, Keyun Qing
  • RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR TREATING LEBER'S CONGENITAL AMAUROSIS-1 (LCA1)
    Publication number: 20220186260
    Abstract: Disclosed are viral vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian guanylate cyclase proteins. Also disclosed are methods for their use in preventing, treating, and/or ameliorating at least one or more symptoms of a disease, disorder, abnormal condition, or dysfunction resulting at least in part from a guanylate cyclase deficiency in vivo. In particular embodiments, the use of recombinant adeno-associated viral (rAAV) vectors to treat or ameliorate symptoms of Leber's congenital amaurosis, as well as other conditions caused by an absence or reduction in the expression of a functional retinal-specific guanylate cyclase 1 (retGC1).
    Type: Application
    Filed: December 1, 2021
    Publication date: June 16, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Shannon E. Boye, William W. Hauswirth, Sanford L. Boye
  • Interactive mixed reality system and uses thereof
    Patent number: 11361516
    Abstract: An interactive mixed reality simulator is provided that includes a virtual 3D model of internal or hidden features of an object; a physical model or object being interacted with; and a tracked instrument used to interact with the physical object. The tracked instrument can be used to simulate or visualize interactions with internal features of the physical object represented by the physical model. In certain embodiments, one or more of the internal features can be present in the physical model. In another embodiment, some internal features do not have a physical presence within the physical model.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 14, 2022
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Samsun Lampotang, David Erik Lizdas
  • Apratyramide therapeutic agents and methods of treatment
    Patent number: 11358989
    Abstract: The invention is directed towards Apratyramide linear depsipeptide compounds, pharmaceutical compositions thereof, and methods of affecting wound healing, and methods of affecting the biological processes involved in wound healing (e.g., inflammation, cell proliferation, tissue granulation, remodeling of scar tissue, etc.).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 14, 2022
    Assignees: University of Florida Research Foundation, Incorporated, Smithsonian Institution
    Inventors: Hendrik Luesch, Weijing Cai, Valerie J. Paul, Lilibeth A. Salvador
  • Amino acid compositions for the amelioration of symptoms of hangover
    Patent number: 11357747
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: June 14, 2022
    Assignees: ENTRINSIC, INC., UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Sadasivan Vidyasagar, Stephen J. Gatto, Daniel B. Dennison
  • ENHANCED HUMAN OPSIN PROMOTER FOR ROD SPECIFIC EXPRESSION
    Publication number: 20220175969
    Abstract: The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 9, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Frank M. Dyka, William W. Hauswirth
  • METHODS AND APPARATUSES FOR FREEFORM ADDITIVE MANUFACTURING OF ENGINEERING POLYMERS
    Publication number: 20220176616
    Abstract: A polymer three-dimensional (3D) printing methodology is disclosed for freeform fabrication of polymeric structures under ambient conditions without the use of printed support structures. The build material can be dissolved in a suitable solvent for 3D printing. The polymer solution can be printed in (e.g., continuously printed using a moving dispensing nozzle) a yield-stress support bath to form an intermediate article. The intermediate article may be liquid or only partially coagulated after being printed into the yield-stress support bath. The yield-stress support bath may be at least partially disposed within a container, and the container may be immersed in a post-treatment coagulation solution to remove some or all of the solvent, causing the build material to fully solidify to form a finished article from the intermediate article.
    Type: Application
    Filed: March 12, 2021
    Publication date: June 9, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Yong HUANG, Ashley M. COMPAAN, Kaidong SONG
  • METHODS AND COMPOSITIONS FOR TREATING CONDITIONS USING RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
    Publication number: 20220175887
    Abstract: Methods and compositions for treating symptoms of conditions such as but not limited to osteoarthritis and rheumatoid arthritis. The methods may feature direct intraarticular injection of a recombinant self-complementary adeno-associated virus (sc-rAAV) with a vector adapted to express a modified IL-1Ra peptide. The methods of the present invention may express a therapeutically effective amount of the modified IL-1Ra peptide so as to ameliorating symptoms associated with the condition being treated.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 9, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Jeffrey S. Bartlett, Steven C. Ghivizzani
  • Method for delivering RNA to neurons to treat herpes infections
    Patent number: 11351273
    Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 7, 2022
    Assignees: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College, University of Florida Research Foundation, Incorporated
    Inventors: David C. Bloom, Alfred S. Lewin, Donna M. Neumann, Zachary L. Watson, Sonal Sanjeev Tuli, Gregory Scott Schultz
  • Cyanobacterial hosts and methods for producing chemicals
    Patent number: 11352601
    Abstract: The present invention relates to recombinant cyanobacterial cells for the production of a chemical compound of interest. In particular, the present invention relates to genetic modifications that introduce one or more heterologous phosphopantetheinyl transferases (PPTases) into a cyanobacterial cell. These cells can, optionally, further comprise heterologous carrier protein and nucleic acid constructs that provide the cyanobacterial cells with the capability of producing chemicals of interest or compounds of interest, such secondary metabolites polyketides, nonribosomal peptides and their hybrids, the three major families of bioactive natural products, of cyanobacteria and other bacterial phyla, secondary metabolites analogs, and unnatural compounds.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 7, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Yousong Ding, Guang Yang
  • Common mode (CM) electromagnetic interference (EMI) filters for reducing radiated EMI in power converters
    Patent number: 11356011
    Abstract: Provided are examples of electromagnetic interference (EMI) filters for reducing radiated EMI in power converters. An example EMI filter includes a common mode (CM) choke located on an input cable connected to a first side of a converter a first set of Y-capacitors located between a primary ground (PGND) node of the converter and a secondary ground (SGND) node of the converter, and a second set of Y-capacitors located between the first side of the converter and the SGND node. A first shielding may be connected to the SGND node. One or more additional shieldings may be inside the first shielding and connected to one of the PGND node or the SGND node. The converter may be one or more of an isolated converter, an LLC resonant power converter, a Flyback converter, a forward converter, or a push-pull power converter.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: June 7, 2022
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Shuo Wang, Juntao Yao, Yiming Li
  • THERAPEUTIC AGENTS AND METHODS OF TREATMENT
    Publication number: 20220169628
    Abstract: The invention is directed towards compounds (e.g., Formula (I)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formula (I)).
    Type: Application
    Filed: February 7, 2020
    Publication date: June 2, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Guangrong Zheng, Daohong Zhou, Pratik Pal, Xingui Liu, Dinesh Thummuri, Wanyi HU, Peiyi Zhang, Dongwen Lyu, Yaxia Yuan, Xuan Zhang
  • Regulation of RAN translation by PKR and eIF2A-P pathways
    Patent number: 11345911
    Abstract: Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: May 31, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Tao Zu
  • Compounds for treating neurodegenerative proteinopathies
    Patent number: 11345738
    Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solveates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 31, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Todd E. Golde, Paramita Chakrabarty
  • Modular prosthetics devices
    Patent number: 11337833
    Abstract: Various examples are provided for modular prosthetic devices and their use. In one example, a device includes a chassis assembly including a joint portion; and an interchangeable module that can be removably attached to the chassis assembly. The interchangeable modules can be configured for use in a wide variety of applications. The interchangeable modules can be quickly exchanged for different activities.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 24, 2022
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Wallace Gregory Sawyer, Brian P. Bartlett, Derek L. Hood